Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Cash from Operations (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Cash from Operations for 3 consecutive years, with 14726000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 0.52% to 14726000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 76751000.0, a 39.47% decrease, with the full-year FY2025 number at 76751000.0, down 39.47% from a year prior.
  • Cash from Operations was 14726000.0 for Q4 2025 at Artiva Biotherapeutics, up from 19201000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 10675000.0 in Q4 2023 to a low of 23024000.0 in Q2 2025.
  • A 3-year average of 15320600.0 and a median of 14688000.0 in 2024 define the central range for Cash from Operations.
  • Biggest YoY gain for Cash from Operations was 0.52% in 2025; the steepest drop was 68.24% in 2025.
  • Artiva Biotherapeutics' Cash from Operations stood at 10675000.0 in 2023, then tumbled by 37.24% to 14650000.0 in 2024, then fell by 0.52% to 14726000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Cash from Operations are 14726000.0 (Q4 2025), 19201000.0 (Q3 2025), and 23024000.0 (Q2 2025).